Christopher Leo

Christopher Leo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MLMengyan Li
Mengyan Li
RRRuodi Ren
Ruodi Ren
KWKunkun Wang
Kunkun Wang
SWShan Wang
Shan Wang
ACAllison Chow
Allison Chow
CLChristopher Leo
Christopher Leo
Homocysteine is an amino acid derived from methionine which is metabolized via vitamin B6 (pyridoxine)- and vitamin B12 (cobalamin)-dependent pathways. Supplementation of B vitamins has been shown to effectively reduce plasma homocysteine levels. Previous research has also demonstrated an association between lower plasma homocysteine levels and decreased risk of myocardial infarction, stroke, and venous thromboembolism. However, whether supplementation of B vitamins is associated with risk reduction in thromboembolic events and confers clinical benefits remains inconclusive. This review examines clinical trials published over the past 29 years to assess the effects of B vitamin supplementation on thrombotic risk reduction and homocysteine metabolism. The findings from these studies are inconsistent, and the impact of B vitamins on thrombosis prevention remains uncertain. Given the conflicting evidence, further clinical and translational research is necessary to clarify the role of B vitamin supplementation in thrombosis risk reduction.

27 February 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
SWShan Wang
Shan Wang
RRRuodi Ren
Ruodi Ren
KWKunkun Wang
Kunkun Wang
CLChristopher Leo
Christopher Leo
MLMengyan Li
Mengyan Li
YLYun Lu
Yun Lu
The prevalence of vitamin D deficiency among intensive care unit (ICU) patients is potentially associated with an increased risk of mechanical ventilation, sepsis, prolonged hospital stays, and mortality. Although ICU patient care has significantly improved in recent years, the role of vitamin D supplementation remains under investigation. A literature review was conducted using PubMed, Web of Science, Embase, and Cochrane databases, focusing on randomized controlled trials published in the past five years on vitamin D supplementation in adult ICU patients. Patients’ baseline vitamin D levels, administration routes, doses, biomarker changes, mechanical ventilation duration, length of hospital stay, and mortality were analyzed. Although vitamin D supplementation appears safe and may reduce ICU stay duration and mechanical ventilation time and improve SOFA scores, its impact on overall mortality remains uncertain. Routine supplementation for all ICU patients is not currently recommended; clinical decisions should consider individual baseline vitamin D levels, patient characteristics, severity of illness, doses, and administration methods.

5 March 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
RRRuodi Ren
Ruodi Ren
AYAndrew Yang
Andrew Yang
ACAllison Chow
Allison Chow
KWKunkun Wang
Kunkun Wang
SWShan Wang
Shan Wang
MLMengyan Li
Mengyan Li
Background and Purpose: The effects of B-vitamin combinations on the prevention of cardiovascular diseases, such as myocardial infarction (MI) and stroke, remain controversial. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) over three decades to evaluate the association between B-vitamin combinations and mortality and arterial thrombotic outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched for RCTs with minimal duration over 24 months published between January 1996 and November 2025. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool. Random-effects models were used in this meta-analysis to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs). Results: Thirteen randomized trials enrolling 68,363 participants across both primary and secondary prevention populations were included. B-vitamin combinations were associated with a nonsignificant reduction in stroke and 3-point major adverse cardiovascular events (MACE) (stroke: RR 0.91, 95% CI 0.81–1.04; MACE: RR 0.93, 95% CI 0.86–1.01). No significant effects were observed for all-cause mortality (RR 1.01, 95% CI 0.96–1.06), cardiovascular mortality (RR 0.97, 95% CI 0.88–1.07), or MI (RR 0.97, 95% CI 0.91–1.03). In primary prevention populations, B-vitamin combinations were associated with significant reductions in stroke (RR 0.79, 95% CI 0.68–0.93) and MACE (RR 0.80, 95% CI 0.69–0.92). A modest reduction in MACE was also observed in secondary prevention populations (RR 0.91, 95% CI 0.83–0.99). Between-study heterogeneity was minimal to low for ischemic outcomes, supporting the robustness of these estimates, whereas substantial heterogeneity was observed for mortality outcomes in secondary prevention populations. Conclusions: The evidence is limited by heterogeneity in trial populations, vitamin formulations and doses, and outcome definitions, with substantial between-study inconsistency for mortality outcomes and imprecision in subgroup estimates derived from a small number of contributing trials. Overall, B-vitamin combinations do not confer consistent benefit for major cardiovascular outcomes but may reduce stroke and MACE in selected primary prevention populations, suggesting that baseline cardiovascular risk and regional folic acid fortification modify treatment effects and should guide future trial design and clinical use.

27 September 2019 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
CLChristopher Leo
Christopher Leo
YWYun Wang
Yun Wang
AMAlexander Mold
Alexander Mold
JQJunik Quintana
Junik Quintana
HSHong Shi
Hong Shi
RPRichard Petrillo
Richard Petrillo
Healthcare givers were recommended to check serum ammonia level for elderly patients with acute‐on‐chronic alteration of mental status. Early initiation of antihyperammonemia therapy may benefit improvement of alteration of mental status. Baseline mental status becomes necessary for diagnose the acute alteration of mental status and monitor the therapeutic process.

6 September 2026 in Pharmacological Research
Verified
Journal Article
Open access
LYLing Yin
Ling Yin
RRRuodi Ren
Ruodi Ren
CLChristopher Leo
Christopher Leo
YLYun Lu
Yun Lu
Tau pathology is strongly associated with neurodegeneration and clinical progression in Alzheimer's disease (AD), positioning it as an important therapeutic target. However, tau-targeted therapies have thus far demonstrated limited and inconsistent translation into meaningful clinical benefit. To examine clinical trials of tau-targeted therapies and explore potential mechanisms underlying their translational disconnect between biological target engagement and clinical outcomes. A structured search of PubMed, MEDLINE, Embase, Cochrane CENTRAL, and related databases was conducted to identify interventional clinical trials targeting tau pathology. Eligible studies included randomized and early-phase trials evaluating monoclonal antibodies, vaccines, antisense oligonucleotides, and small-molecule aggregation inhibitors. Findings were synthesized using a structured narrative approach due to heterogeneity in study design, disease populations, therapeutic mechanisms and clinical end points. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Eleven clinical trials were included, comprising seven monoclonal antibody studies, two vaccine trials, one antisense oligonucleotide study, and one small-molecule aggregation inhibitor study. Across monoclonal antibody and vaccine programs, biomarker modulation and target engagement were observed in some studies, yet these findings did not consistently translate into meaningful reductions in cognitive or functional decline. The antisense oligonucleotide BIIB080 demonstrated substantial reductions in cerebrospinal fluid tau biomarkers, supporting biological activity and target engagement; however, clinical efficacy remains to be established. Similarly, the small-molecule aggregation inhibitor LMTM did not demonstrate consistent clinical benefit in phase 3 trials. Most studies exhibited low risk of bias or some concerns, suggesting that methodological limitations alone may not fully explain the observed translational challenges. Tau-targeted therapies highlight a translational gap between biological activity and clinically meaningful benefit across multiple therapeutic mechanisms. Emerging evidence suggests that disease-stage timing, biomarker interpretation, tau heterogeneity, and aging-related factors may contribute to this disconnect. Future strategies will likely require earlier, and more biologically stratified intervention approaches, improved biomarker validation, and combination paradigms addressing the multifactorial complexity of neurodegenerative disease.

5 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MLMengyan Li
Mengyan Li
RRRuodi Ren
Ruodi Ren
KWKunkun Wang
Kunkun Wang
SWShan Wang
Shan Wang
ACAllison Chow
Allison Chow
CLChristopher Leo
Christopher Leo
Homocysteine is an amino acid derived from methionine, metabolized via vitamin B6 (pyridoxine)- and vitamin B12 (cobalamin)-dependent pathways. Supplementation of B vitamins has been shown to effectively reduce plasma homocysteine levels. Previous research has also demonstrated an association between lower plasma homocysteine levels and decreased risk of myocardial infarction, stroke and venous thromboembolism. However, it remains inconclusive if supplementation of B vitamins is associated with risk reduction in thromboembolic events and confers clinical benefits. This article aims to review clinical trials in the last ten years to determine the effects of B vitamin supplementation in plasma homocysteine lowering, and evaluate its impact on reducing the risk of arterial and venous thromboembolism.